Skip to main content

Table 2 Characteristics of 11 patients with not evaluable or uncertain brain response

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Case No

Study drug started

Study drug ended

Reason for ending drugs

Best systemic response

Brain PD by symptoms and MRI

Reason for not evaluable brain response during study period

Inclusion*

1

Consent withdrawal

     

2

2007.3.22

2007.3.29

Unknown

Unknown

Unknown

No follow-up MRI

3

2008.2.19

2008.3.11

Unknown

Unknown

Unknown

No follow-up MRI

4

2008.2.15

2008.4.1

Systemic PD

PD

Unknown

No follow-up MRI

5

2007.3.22

2007.4.17

Systemic PD

PD

Unknown

No follow-up MRI

6

2007.8.07

2007.9.17

Systemic PD

PD

2008.2.18

MRI long after ending study drug

,

7

2007.4.02

2008.5.21

Brain PD

PR

2008.6.3

No MRI until brain symptoms

,

8

2007.3.30

2007.6.28

Systemic PD

PR

2007.11.12

Metastatectomy prior to study started

9

2007.11.30

2008.2.5

Systemic PD

SD < 6mo

2008.7.30

Metastatectomy prior to study started

10

2008.4.8

2008.11.11

Systemic PD

SD ≥ 6mo

2008.11.7

Metastatectomy prior to study started

11

2007.9.5

2007.12.31

Systemic PD

SD < 6mo

2008.2.3

Gamma knife surgery prior to study started

  1. * Included denominator for , brain response rate; , brain PFS analysis.
  2. These 11 patients excluded the association between brain response and systemic response (Table 3).